We analyzed long-term outcomes of myeloablative stem cell transplantation (SCT) in 292 adults with Philadelphia (Ph)-negative acute lymphoblastic leukemia (ALL). Donors were related (RD; n ¼ 132), unrelated (URD; n ¼ 68; 30 well-matched (WM), 19 partially matched (PM), 19 mismatched (MM)) and autologous (AUTO; n ¼ 92). After a median follow-up of 85 months, the risk of relapse was higher for AUTO-SCT than for RD-SCT (Po0.001). MM-URD-SCT yielded higher risk of nonrelapse mortality than RD-SCT (P ¼ 0.010). As a result, diseasefree survival (DFS) at 5 years was inferior using AUTO (46.1%; P ¼ 0.010) or MM-URD (26.3%; P ¼ 0.036), whereas DFS from other donor sources was approximately equivalent (53.5% for RD, 63.3% for WM-URD and 57.0% for PM-URD). Other factors associated with poorer DFS included SCT beyond first complete remission (CR), older age and adverse cytogenetics. In a pairwise comparison of outcomes between RD-SCT and AUTO-SCT for patients in first CR, the inferiority of AUTO-SCT was observed, particularly in high-risk patients. Conversely, in standard-risk patients, AUTO-SCT yielded comparable outcomes to RD-SCT. SCT using RD, WM-URD or PM-URD may be considered the best donor sources for adult high-risk Ph-negative ALL.
Introduction
Advances in chemotherapeutic treatment of adult acute lymphoblastic leukemia (ALL) have resulted in complete remission (CR) rates of 74-93%; however, only 35% of these patients achieve long-term disease-free survival (DFS). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Because the high incidence of relapse is a main cause of treatment failure in adults with ALL, optimal postremission therapy, in particular, the efficacy of stem cell transplantation (SCT) is a critical issue.
The graft-versus-leukemia effect for adult ALL has now been definitely confirmed from several 'matched related donor (RD) versus no donor' comparisons. [11] [12] [13] However, no definite conclusions can be extracted from these data, as to whether or not there is a survival advantage to RD-SCT over other therapeutic modalities for both high-risk and standard-risk patients. Even so, allogeneic SCT clearly benefits certain high-risk patients, such as those with Philadelphia (Ph) chromosome -positive ALL. Importantly, the advent of imatinib or other tyrosine kinase inhibitors has significantly changed the outlook for adults with Ph-positive ALL.
14-17 Earlier, we also reported on the positive impact of imatinib on outcome of allogeneic SCT in adults with Ph-positive ALL. 18, 19 Conversely, the survival benefit of allogeneic SCT for adults with Ph-negative ALL remains uncertain.
Another important point for consideration is that 'RD versus no donor' analysis is becoming outmoded; as in many studies, patients previously in a 'no donor' category are now undergoing human leukocyte antigen (HLA)-matched unrelated donor (URD)-SCT. There is increasing evidence to show that URD-SCT could yield results similar to those achieved by RD-SCT. [20] [21] [22] [23] [24] We report on long-term outcomes of total body irradiation (TBI)-based myeloablative SCT in 292 consecutive adults with Ph-negative ALL who received SCT from RD, URD and autologous (AUTO) sources, at the Catholic Blood and Marrow Transplantation Center. Here, URD sources were classified as well-matched (WM), partially matched (PM) or mismatched (MM) based on a new proposed guideline from the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research (CIBMTR). 25 This allows a unique opportunity to examine transplantation outcomes from a single center using consistent chemotherapy, preparation and supportive care strategies. The present study focused on the following questions for adults with Ph-negative ALL: (1) How different are the outcomes of SCT according to the donor sources? (2) Which factors are important for the determination of transplantation outcome? (3) Which URD should be chosen? (4) Is there a role for AUTO-SCT plus long-term maintenance chemotherapy?
Patients and methods

Treatment policy
At our center, it is the treatment policy to offer allogeneic or AUTO transplantation according to the donor availability and the presence of high-risk features. All patients (aged 15-65 years) with ALL are HLA typed after induction therapy. If an HLA fully matched RD is available, RD-SCT is offered to any patient, irrespective of risk assessment, after the completion of first consolidation course. In addition, if a suitably matched URD (p2-allele-MM donor) is available, URD-SCT is offered to highrisk patients as early as possible, which is dependent mainly on the speed of coordination process. Remaining patients who have no available RD (standard-risk) or URD (high-risk) are offered to receive AUTO-SCT after the completion of second consolidation courses. To be eligible for myeloablative SCT, patients must be p50 years of age (for RD-SCT and URD-SCT) and p65 years of age (for AUTO-SCT). Moreover, all patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and no major organ dysfunction. Since 2000, reduced-intensity SCT is being offered to high-risk patients who have a donor, but are not eligible for myeloablative SCT. 26 
Study population
Between 1995 and 2008, a total of 442 patients underwent transplant from RD, URD or AUTO donor sources. To better evaluate risk factors affecting TBI-based myeloablative transplantation outcomes in Ph-negative ALL, 125 Ph-positive ALL patients (102 myeloablative transplants and 23 reducedintensity transplants) and 25 Ph-negative ALL patients who received reduced-intensity transplantation were excluded. The analyzed study population was composed of 292 consecutive adults with ALL who received TBI-based myeloablative SCT from RD, URD or AUTO sources. All patients and donors provided written informed consent, and the treatment protocol was approved by the Institutional Review Board of The Catholic University of Korea. This study was conducted in accordance with the Declaration of Helsinki. Data were analyzed as of December 2009.
Treatment before transplantation
Induction therapy was started with hyper-fractionated cyclophosphamide (300 mg/m 2 , every 12 h, days 1-3), vincristine
, maximum dose 2 mg, days 4 and 11), idarubicin (12 mg/m 2 , days 4 and 11), and dexamethasone (40 mg, days 1-4 and days [11] [12] [13] [14] . 18, 19, 26 Subsequently, patients in CR received consolidation courses consisting of high-dose cytarabine (2 g/m 2 , every 12 h, days 1-5) and mitoxantrone (12 mg/m 2 , days 1-2) therapy (at each odd cycle of consolidation) alternating with the above induction regimens (at each even cycle of consolidation), which is dependent on the donor availability and the time of transplantation. Patients who did not achieve CR after induction or relapsed leukemia received intensified salvage chemotherapy, namely, cytarabine (2 g/m 2 , every 12 h, days 1-4), mitoxantrone (12 mg/m 2 , days 1-4) and etoposide (100 mg/m 2 , days 5-7). Patients achieving CR after this salvage chemotherapy received an additional consolidation course (cytarabine-mitoxantrone). Each course of chemotherapy should be started after leukocyte counts were higher than 3 Â 10 9 /l and platelet counts higher than 100 Â 10 9 /l. Central nervous system prophylaxis was performed by intrathecal administration of triple agents (methotrexate 12 mg, cytarabine 40 mg and methylprednisolone 50 mg; 6 times in total).
Preparative regimen and graft-versus-host disease (GVHD) prophylaxis
The preparative regimen for allogeneic transplants in CR1 consisted of TBI (13.2 Gy) and cyclophosphamide (120 mg/kg), and for allogeneic transplants beyond CR1 or AUTO transplants, TBI (12 Gy), cytarabine (12 g/m 2 ) and melphalan 
Definitions
Patients were classified as the high-risk group if they met one of the following criteria at diagnosis: (1) adverse cytogenetics (t(4;11), t(8;14), complex karyotype (X5 abnormalities) or low hypodiploidy-near triploidy); (2) older age (X35 years); (3) high-leukocyte counts (X30 Â 10 9 /l for B-precursor ALL, X100 Â 10 9 /l for T-precursor ALL) or delayed CR1 (428 days of induction therapy). All other patients were classified as the standard-risk group. Cytogenetic classification was performed according to the classification proposed by the Medical Research Council (MRC)/ECOG and the Southwest Oncology Group, 27, 28 and level-4 group of cytogenetic abnormalities was defined as adverse cytogenetics for this study. CR was defined as the reconstitution of normal bone marrow cellularity with o5% leukemic blasts, together with an absolute neutrophil count of 41.5 Â 10 9 /l and a platelet count of 4100 Â 10 9 /l. Relapse was defined by the reappearance of 45% leukemic cells in bone marrow aspirates or extramedullary leukemia in patients with earlier documented CR. Patients were considered refractory if peripheral blood blasts or extramedullary disease had not been eliminated, or if bone marrow blasts had not been reduced o5%, or both. GVHD was diagnosed and graded using earlier published criteria.
29,30
Statistical analysis
Main end points of this study included overall survival (OS), DFS, non-relapse mortality (NRM) and relapse. We calculated OS from the date of transplantation until the date of death, or the last follow-up. When calculating DFS, both relapses and deaths in remission were counted as adverse events. 31, 32 On the other hand, NRM and relapse were calculated using cumulative incidence estimates and by taking into account the competing risk structure. 33 Survival curves for OS and DFS were plotted using the Kaplan-Meier method and compared using the log-rank test, 31, 32 whereas those for NRM and relapse were plotted according to cumulative incidence estimates and compared by the Gray test. 33 The prognostic significances of presenting and transplant covariates affecting OS and DFS were determined using the Cox proportional hazard model. Factors were considered significant if they had an associated P-value of o0.05 as determined by the likelihood ratio test, using two-tailed significance testing. On the other hand, the prognostic significances of covariates affecting NRM and relapse were determined using the semi-parametric model known as the 'proportional hazard model for sub-distribution of competing risks.' Donor-specific SCT outcomes for Ph-negative ALL S Lee et al Table 2 Multivariate analyses of outcomes in adults with Philadelphia-negative acute lymphoblastic leukemia who underwent total body irradiation-based myeloablative SCT 
Results
Patient characteristics
Main presenting clinical and biological features at the time of diagnosis and transplantation for all transplants are summarized in Table 1 (Figure 1a ). According to results from multivariate analysis (Table 2) , the relative risk (RR) of relapse was significantly higher for AUTO-SCT than for RD-SCT (RR, 2.70; 95% confidence interval (CI), 1.65-4.42; Po0.001), whereas other URD-SCT had relapse risk similar to that of . As a result, DFS at 5 years was inferior using AUTO (46.1%; RR, 1.69; 95% CI, 1.14-2.51; P ¼ 0.010) or MM-URD (26.3%; RR, 2.03; 95% CI, 1.05-3.95; P ¼ 0.036), compared with RD sources, although DFS from all other donor sources was approximately equivalent (53.5% for RD, 63.3% for WM-URD, and 57.0% for PM-URD; Figure 1c ). In addition, older age (P ¼ 0.020), level-4 cytogenetics (P ¼ 0.041) and transplantation in CR2 or later (Po0.001) were associated with poorer DFS ( Table 2) . As with DFS, OS was lower using AUTO (P ¼ 0.020) or MM-URD (P ¼ 0.031). Older age (P ¼ 0.039), level-4 cytogenetics (P ¼ 0.049), and transplantation in CR2 or later (Po0.001) were associated with poorer OS (Figure 1d and Table 2 ).
Transplants in CR1
Among 241 transplants in CR1, the 5-year cumulative incidence of relapse was highest for AUTO (45.8%; RR, 3.37; 95% CI, 1.90-6.00; Po0.001), compared with RD sources (20.7%). Conversely, there was no difference between RD and URD sources (18.3% for WM-URD, 20.0% for PM-URD, 12.5% for MM-URD). In terms of the cumulative incidence of NRM, MM-URD sources yielded higher NRM (45.5%; RR, 3.52; 95% CI, 1.19-10.43; P ¼ 0.023) than RD-SCT (18.2%), although no difference was found between RD and the remaining donor sources (20.4% for WM-URD, 21.4% for PM-URD, 8.3% for AUTO). As a result, DFS at 5 years was lower for patients receiving either AUTO (49.5%; RR, 1.86; 95% CI, 1.19-2.91; P ¼ 0.007) or MM-URD (45.5%; RR, 2.28; 95% CI, 0.88-5.88; P ¼ 0.089), compared with RD sources (64.4%), although the difference between MM-URD and RD was at the margin of statistical significance. Transplantation using WM-URD (64.0%) or PM-URD (62.9%) showed similar DFS to RD-SCT. As with DFS, OS was lower using AUTO (P ¼ 0.017) or MM-URD (P ¼ 0.090; Figure 2 ). Other factors affecting transplantation outcomes for this cohort were similar to those for the entire cohort ( Table 2) .
In a pairwise comparison of outcomes between RD-SCT and AUTO-SCT according to risk group for this cohort, the inferiority of AUTO-SCT was observed, particularly in high-risk patients, in terms of the risk of relapse (54.7 versus 21.8%, Po0.001), DFS (40.4 versus 61.8%, P ¼ 0.002) and OS (41.8 versus 62.6%, P ¼ 0.006) at 5 years, compared with RD-SCT. Conversely, in standard-risk patients, AUTO-SCT yielded comparable outcomes to those of RD-SCT (Figure 3 ).
GVHD and risk factors for allogeneic transplants
In a separate analysis including only patients who received allogeneic RD or URD transplantation (n ¼ 200), the cumulative incidence of acute GVHD at 100 days was 48.2±3.4%. Of the 175 patients who survived at least 100 days with sustained engraftment after transplantation, 83 developed chronic GVHD (33 limited, 50 extensive), which resulted in a 5-year cumulative incidence of 47.4±3.9%. No significant difference in the incidence of acute and chronic GVHD was observed between RD and URD sources (data not shown). As shown in Table 3 and Figure 4 , multivariate analysis for this cohort showed that the most powerful predictive factor affecting relapse, DFS and OS was disease status at the time of transplantation. For the 157 transplants in CR1, the cumulative incidence of relapse, DFS and OS at 5 years was 20.3, 62.5 and 63.9%, respectively. Compared with transplants in CR1, transplants in CR2 or later had significantly higher risk of relapse and poorer DFS and OS. Presence of chronic GVHD, especially the limited type, was also found to be significantly associated with lower relapse and better DFS and OS. Cumulative incidence of relapse at 5 years for transplants without chronic GVHD was higher than that for transplants with limited chronic GVHD (45.0 versus 12.0%; RR, 5.53; 95% CI, 1.68-18.18; P ¼ 0.005). No difference in relapse risk was observed between transplants with limited chronic GVHD and those with extensive chronic GVHD. Transplants with limited chronic GVHD had better DFS (85.4%) than those with extensive chronic GVHD (60.6%; RR, 3.28; 95% CI, 1.12-9.67; P ¼ 0.031) or those without chronic GVHD (48.8%; RR, 5.13; 95% CI, 1.83-14.38; P ¼ 0.002). As with DFS, transplants with extensive chronic GVHD (P ¼ 0.031) or those without chronic GVHD (P ¼ 0.002) had poorer OS than those with limited chronic GVHD.
Discussion
To the best of our knowledge, this is the largest report issued by a single center on adults with Ph-negative ALL treated by myeloablative SCT using consistent chemotherapy, preparation and supportive care strategies. Our data indicate that although all URD transplants had high-risk factors, transplantation from Table 3 Multivariate analyses of outcomes in adults with Philadelphia-negative acute lymphoblastic leukemia who underwent total body irradiation-based myeloablative allogeneic SCT (n ¼ 200) Donor-specific SCT outcomes for Ph-negative ALL S Lee et al WM-or PM-URD can result in a similar DFS and OS, between 57 and 63% at 5 years, compared with RD-SCT. Conversely, MM-URD transplants had an unacceptably high NRM, and AUTO transplants were associated with a high risk of relapse.
Together with donor sources, disease status at the time of transplantation was an important determinant of outcomes. Our findings are supported by those from other studies that demonstrate a similar outcome of RD-SCT and URD-SCT for adult high-risk ALL (including Ph-positive ALL). [20] [21] [22] [23] [24] According to Kiehl et al., 20 although more patients received RD-SCT in CR1, no difference in 5-year DFS was observed between RD-SCT (n ¼ 103; 42%) and URD-SCT (n ¼ 118; 45%). Transplants in CR1 had a survival advantage than those in CR2 or later. Regarding the impact of HLA matching on transplantation outcomes, the CIBMTR data showed a similar finding to ours, in which MM-URD transplants had a higher NRM than WM-or PM-URD transplants for adult Ph-negative ALL in CR1 (n ¼ 169; 83 versus 40% versus 41% at 5 years). 23 Tomblyn et al.
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(n ¼ 623; including 203 adult patients) also demonstrated that outcomes were similar for transplantation using RD, WM-URD, PM-URD or cord blood sources, although MM-URD or AUTO sources yielded worse outcomes. Transplants in CR1 had a Donor-specific SCT outcomes for Ph-negative ALL S Lee et al better survival compared with those beyond CR1. In conjunction with these results and our data, transplantation from WM-or PM-URD is an appropriate option for adult high-risk Ph-negative ALL, especially during CR1. Several potential factors could account for our somewhat better outcomes for WM-URD and PM-URD SCT in comparison with those obtained by other studies. [20] [21] [22] [23] The first is the relative youth of our cohort, with particularly higher proportions of younger URD transplants (median age, 21 years; X35 years, 18%). Here, we regarded 50 years as the upper age limit for myeloablative allogeneic SCT. In contrast, Kiehl et al. 20 reported a 5-year DFS of 45% for 32 URD transplants in CR1 (median age, 29 years; range, 17-57 years). The CIBMTR data showed that 5-year OS for URD transplants in CR1 was 39%. 23 In this report, B40% of patients were over 35 years (median age, 33 years; range, 16-59 years). In accordance with other studies, 20, 34 our data also showed that older age was associated with higher NRM and lower survival. Thus, the relevance of age factor with regard to transplantation outcomes should be considered. Second, to have URD-SCT, our patients actually had to survive for a median of 6 months. This inherent selection bias may improve the outcomes of URD-SCT. Additional potential factors included a more uniform strategy for chemotherapy, TBI-based preparation, GVHD prophylaxis, choice of bone marrow as a main allograft source and center effects.
A surprising finding of the present study is that AUTO-SCT yielded comparable outcomes to RD-SCT in standard-risk patients. Our results are supported by those from the French LALA group. 35 They showed that 10-year OS following RD-SCT was superior to AUTO-SCT in high-risk patients (44 versus 10%), whereas there was no difference in standard-risk patients (49 versus 49%). However, some cautions in interpretation of our data are important. Our study is limited by difficulty of direct comparison between AUTO-and RD-SCT, lack of data from patients receiving chemotherapy-alone, and lack of information on minimal residual disease significance. In addition, our patients actually had to survive after achieving CR1 for a median 5.4 months to receive AUTO-SCT. This inherent bias is a possible cause of our good results, especially for standard-risk patients (relapse 26%, DFS 71%, OS 71%). In other studies (relapse 49-57%, DFS 32-45%, OS 46-49%), median interval from CR1 to AUTO-SCT was 2-3 months. 12, 13, 35 Our good results may also be explained by a uniform strategy for 2-years' post-AUTO maintenance therapy using triple agents. In the Royal Marsden studies, 36, 37 patients receiving 2-3 agents had lower relapse rates and superior DFS compared with those receiving 0-1 agent, especially for standard-risk patients. In the French LALA stuides, 8, 35 although AUTO-SCT showed no superiority over chemotherapy, fewer late relapses were observed in AUTO transplants. These results suggest that post-AUTO maintenance may reduce the relapse risk in standard-risk ALL.
The question of which subgroups of ALL can benefit from allogeneic SCT remains to be answered. A meta-analysis of seven published studies demonstrated the survival advantage of RD-SCT (versus AUTO/chemotherapy) in high-risk patients. 11 Conversely, two recent studies from the MRC/ECOG 12 and the Dutch-Belgian HOVON Group 13 demonstrated the survival benefit of RD-SCT in standard-risk patients. This discrepancy is due mainly to differing definitions of high-risk features and variable treatment strategies across each of the studies. This raises an important question as to whether or not the recommendation of URD-SCT for standard-risk ALL is reasonable when no RD is available. A prospective study 38 demonstrated that 10/10 allelic-matched URD-SCT led to outcomes similar to RD-SCT in standard-risk hematological malignancy. This is an important issue that will need to be considered in the near future. In addition, better estimates by minimal residual disease testing will continue to stratify patients for risk of relapse and allow further individualization of therapy.
In summary, our long-term data suggest that outcomes are similar for transplantation using SD, WM-URD or PM-URD sources, and that these may be considered the best donor sources for adults with Ph-negative ALL, especially for those with high-risk features. Given the refinement of HLA typing and the application of new drugs, indications for transplantation in adult Ph-negative ALL should be continuously evaluated in light of procedural improvements.
